Physician

Lane D Ziegler, DO

According to 2025 Medicare claims, Lane Ziegler, DO (NPI: 1619959863) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33777-1206.

Ziegler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 544 traditional Medicare patients, billed 209,249 HCPCS/CPT codes, and received $3,291,729 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,354 prescription claims across 266 beneficiaries totaling $2,352,584 in drug costs, led by Xtandi (Enzalutamide). 2022 DME data shows 17 claims. Open Payments data shows 52 records totaling $1,112. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	957	263,352	$2,823,187
2016	966	406,477	$3,596,133
2017	908	279,539	$2,687,286
2018	798	330,298	$3,598,122
2019	746	311,313	$3,413,209
2020	526	273,984	$3,738,730
2021	583	226,357	$3,225,252
2022	535	184,144	$2,319,709
2023	553	209,554	$3,107,623
2024	544	209,249	$3,291,729

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	280	1,959	$2,233,538
2016	269	2,251	$2,654,252
2017	283	2,260	$3,297,114
2018	232	1,751	$3,058,263
2019	211	1,397	$2,276,523
2020	186	1,353	$2,481,500
2021	202	1,503	$2,994,884
2022	225	1,291	$2,754,270
2023	236	1,374	$2,141,051
2024	266	1,354	$2,352,584

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	42	310	$74,860
2016	N/R	139	$7,801
2017	N/R	65	$11,896
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	28	$2,576
2021	N/R	N/R	N/R
2022	N/R	17	$1,784
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	137	242	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	314	1,010	$65
96372	Injection of drug or substance under skin or into muscle	118	550	$10
36415	Insertion of needle into vein for collection of blood sample	395	1,438	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	398	1,593	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	25	750	$350,042
Pomalyst	Pomalidomide	15	420	$342,368
Imbruvica	Ibrutinib	21	588	$340,821
Revlimid	Lenalidomide	16	441	$277,578
Xarelto	Rivaroxaban	18	1,200	$21,692

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	52	$1,112	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lane D. Ziegler, DO?

Tedicare shows public-source Medicare data for Lane D. Ziegler, DO (NPI 1619959863), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lane D. Ziegler, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lane D. Ziegler, DO?

Lane D. Ziegler, DO is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Lane D. Ziegler, DO have Open Payments data?

Lane D. Ziegler, DO has 52 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.